ArticleJournal of autoimmunity2013
A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.
Article in Journal of autoimmunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 40 citations in OpenAlex.
- The CD74 inhibitor DRhQ improves short-term memory and mitochondrial function in 5xFAD mouse model of Aβ accumulation.Metabolic brain disease · 2025Article
- MIF contribution to progressive brain diseases.Journal of neuroinflammation · 2024Review
- Integrative Bioinformatics Analysis of mRNA Expression Profiles of Mice to Explore the Key Genes Involved in Crim1 Mutation-Induced Congenital Cataracts.Biochemical genetics · 2023Article
- "Near Cure" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct.Cellular immunology · 2022Article
- Brief report: Enhanced DRα1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice.Cellular immunology · 2021Article
- Article
- Partial MHC/neuroantigen peptide constructs attenuate methamphetamine-seeking and brain chemokine (C-C motif) ligand 2 levels in rats.European journal of pharmacology · 2020Article
- Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.Metabolic brain disease · 2019Article
- A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.Journal of neuroinflammation · 2019Review
- Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.Frontiers in immunology · 2018Article
- MIF and D-DT are potential disease severity modifiers in male MS subjects.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.Metabolic brain disease · 2017Article
- Partial MHC class II constructs as novel immunomodulatory therapy for stroke.Neurochemistry international · 2017Review
- Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Neurochemistry international · 2017Article
- DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.Translational stroke research · 2017Article
- Sex-dependent treatment of chronic EAE with partial MHC class II constructs.Journal of neuroinflammation · 2017Article
- Sex differences in the immune response to experimental stroke: Implications for translational research.Journal of neuroscience research · 2017Review
- Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.Metabolic brain disease · 2016Article
- Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells.Stem cells translational medicine · 2015Article
- The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis.Metabolic brain disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Treatment with partial (p)MHC class II-β1α1 constructs (also referred to as recombinant T-cell receptor ligands - RTL) linked to antigenic peptides can induce T-cell tolerance, inhibit recruitment of inflammatory cells and reverse autoimmune diseases. Here we demonstrate a novel regulatory pathway that involves RTL binding to CD11b(+) mononuclear cells through a receptor comprised of MHC class II invariant chain (CD74), cell-surface histones and MHC class II itself for treatment of experimental autoimmune encephalomyelitis (EAE). Binding of RTL constructs with CD74 involved a previously unrecognized MHC class II-α1/CD74 interaction that inhibited CD74 expression, blocked activity of its ligand, macrophage migration inhibitory factor, and reduced EAE severity. These findings implicate binding of RTL constructs to CD74 as a key step in both antigen-driven and bystander T-cell tolerance important in treatment of inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.